SpringWorks Therapeutics, Inc.
SWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.32 | 6.15 | -0.11 | -0.07 |
| FCF Yield | -6.72% | -9.99% | -12.39% | -4.32% |
| EV / EBITDA | -9.41 | -6.25 | -4.80 | -16.78 |
| Quality | ||||
| ROIC | -56.68% | -52.88% | -47.85% | -40.67% |
| Gross Margin | 93.45% | 92.25% | 69.16% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.69 | 0.58 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 214.70% | – | -44.00% | – |
| Free Cash Flow Growth | 21.78% | -34.01% | -32.23% | -295.62% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 0.50 | 0.23 | 0.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.23 | 0.14 | 0.00 | 0.00 |
| Cash Conversion Cycle | 28.87 | -3,315.77 | -1,542.01 | -2,554.26 |